UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

Filed by the Registrant  x☒                             Filed by a party other than the Registrant  ¨☐

Check the appropriate box:

REGENXBIO Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

REGENXBIO Inc.

9712 Medical Center Drive,9600 Blackwell Road, Suite 100210

Rockville, MD 20850

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

To Be Held On June 1, 2016

Dear Stockholder:

You are cordially invited to attend the Annual Meeting of Stockholders (the Annual Meeting)“Annual Meeting”) of REGENXBIO Inc., a Delaware corporation (the Company)“Company”). The Annual Meeting will be held on June 1, 2016,May 31, 2019, at 9:00 a.m. local time at the Company’s offices located at 97129714 Medical Center Drive, Suite 100, Rockville, Maryland 20850 for the following purposes:

The record date for the Annual Meeting is April 7, 2016.

Only stockholders of record at the close of business on that date mayApril 1, 2019 are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. A complete list of such stockholders will be available for examinationinspection at ourthe Company’s offices in Rockville, Maryland during normal business hours for a period of ten10 days prior to the Annual Meeting.

YOUR VOTE IS IMPORTANT!

Your vote is important. Please voteWhether or not you plan to attend the Annual Meeting in person, please submit your proxy by usingtelephone or over the internet, or by telephone or, if you received a paper copy of thecompleting, signing, dating and returning your proxy card by mail, by signing and returningor voting instruction form so that your shares will be represented at the enclosed proxy card.Annual Meeting. Instructions for your voting options are described onin the Company’s proxy statement for the Annual Meeting, Notice of Internet Availability of Proxy Materials or proxy card.

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 31, 2019:

ImportantThe Company’s Notice Regarding the Availability of Proxy Materials for the StockholdersAnnual Meeting, to be held on June 1, 2016. The Proxy Statement and Annual Report onForm 10-K for the

fiscal year ended December 31, 2018 are available atwww.proxyvote.com.www.proxyvote.com.

Your Board of Directors unanimously recommends you vote the proxy card “FOR” the Company’s two director nominees, Allan M. Fox and Camille Samuels and “FOR” Proposal 2.

By Order of the Board of Directors,

Kenneth T. Mills President and Chief Executive Officer

Rockville, Maryland April 11, 2019

This Proxy Statement is first being mailed to the stockholders of the Board of Directors,

Kenneth T. Mills

President and Chief Executive Officer

Rockville, Maryland

April 18, 2016

This notice of Annual Meeting and accompanying proxy statement are being distributed or made available to stockholdersCompany on or about April 18, 2016.11, 2019.

TABLE OF CONTENTS

i

REGENXBIO Inc.

9712 Medical Center Drive,9600 Blackwell Road, Suite 100210

Rockville, MD 20850

PROXY STATEMENT

FOR THE 2016 ANNUAL MEETING OF STOCKHOLDERS

June 1, 2016

This proxy statement and proxy card areProxy Statement is furnished in connection with the solicitation of proxies to be voted at the 20162019 Annual Meeting of Stockholders (the Annual Meeting)“Annual Meeting”) of REGENXBIO Inc. (sometimes referred to as we, the Company or REGENXBIO), which will be held on June 1, 2016,May 31, 2019, at 9:00 a.m. local time at the Company’s offices located at 97129714 Medical Center Drive, Suite 100, Rockville, Maryland 20850.

When this Proxy Statement refers to “REGENXBIO,” the “Company,” “we,” “us” or “our,” it is referring to REGENXBIO Inc.

We are making this proxy statementProxy Statement and our Annual Report onForm 10-K for the fiscal year ended December 31, 2018 (the “Annual Report”) available to stockholders at www.proxyvote.com. On or about April 18, 2016,11, 2019, we will begin mailing to certain of our stockholders a noticeNotice of Internet Availability of Proxy Materials (the Notice)“Notice”) containing instructions on how to access and review this proxy statementProxy Statement and ourthe Annual Report on Form 10-K at that website.Report. The Notice also instructs you how you may submit your proxy over the internet or via telephone. If you would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting those materials included in the Notice.

QUESTIONS AND ANSWERS ABOUT THISTHE PROXY MATERIALMATERIALS AND VOTING

Why am I receiving this proxy statementProxy Statement and a related proxy card?

You have received these proxy materials because you owned shares of REGENXBIO common stock as of April 7, 2016,1, 2019, the record date for the Annual Meeting (the “Record Date”), and our Board of Directors (the “Board”) is soliciting your proxy to vote at the Annual Meeting. This proxy statementProxy Statement describes issuesmatters on which we would like you to vote at the Annual Meeting. It also gives you information on these issuesMeeting so that you can make an informed decision.

Why did I receive a Notice of Internet Availability of Proxy Materials in the mail instead of a printed set of proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission (SEC)(the “SEC”), we are permitted to furnish our proxy materials over the internet to our stockholders by delivering athe Notice in the mail. As a result, only stockholders who specifically request a printed copy of the proxy statementProxy Statement will receive one. Instead, the Notice instructs stockholders on how to access and review the proxy statementProxy Statement and Annual Report on Form 10-K over the internet at www.proxyvote.com. The Notice also instructs stockholders on how they may submit their proxy overvia telephone or the internet or telephone.internet. If a stockholder who received a Notice would like to receive a printed copy of our proxy materials, such stockholder should follow the instructions for requesting these materials contained in the Notice.

How may I vote at the Annual Meeting?

You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement.Proxy Statement. However, you do not need to attend the meetingAnnual Meeting to vote your shares. Instead, you may simply follow the instructions below to submit your proxy via telephone or on the internet. If you received a printed set of materials, you may also vote by mail by completing, signing, dating and returning the proxy card.

When you vote, regardless of the method used, you appoint Kenneth T. Mills, our President and Sara Garon BerlChief Executive Officer (“CEO”), and Patrick J. Christmas, our General Counsel, as your representatives (or proxyholders) atfor the Annual Meeting. They will vote your shares at the Annual Meeting as you have instructed them or, if an issuea matter that is not on the proxy card comes up for vote, in accordance with their best judgment. This way, your shares will be voted whether or not you attend the Annual Meeting.

Who is entitled to vote at the Annual Meeting?

Only stockholders of record at the close of business on April 7, 2016, the record date for the Annual Meeting,Record Date will be entitled to vote at the Annual Meeting. On the record date,Record Date, there were 26,338,32936,611,157 shares of the Company’sour common stock outstanding. All of these outstanding shares are entitled to vote at the Annual Meeting (one vote per share of common stock) in connection with the matters set forth in this proxy statement.Proxy Statement.

In accordance with Delaware law, aA list of stockholders entitled to vote at the meeting will be available at the place of the Annual Meeting on June 1, 2016 and will be accessible for ten10 days prior to the meetingAnnual Meeting at our principal place of business, 9712 Medical Center Drive,9600 Blackwell Road, Suite 100,210, Rockville, MDMaryland 20850, between the hoursduring ordinary business hours.

What is a stockholder of 9:00 a.m.record and 5:00 p.m. local time.

How dohow can I vote?vote if I am a stockholder of record?

If, on April 7, 2016,the Record Date, your shares of common stock were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. Stockholders of record may vote by usingvia the internet, by telephone or mail (if you received a proxy card by mail) by mail as described below. Stockholders also may attend the meeting and vote in person. If you hold shares through a bank, broker or other nominee, please refer to your proxy card, Notice or other information forwarded by your bank, broker or other nominee to see which voting options are available to you.

The method you use to vote will not limit your right to vote at the Annual Meeting if you decide to attend in person. Written ballots will be passed out to anyone who wants to vote at the Annual Meeting. If you holdIn all cases, your shares will be voted according to your instructions.

What is a beneficial owner of shares and how can I vote if I am a beneficial owner?

If, on the Record Date, your shares of common stock were not held in your name, but rather were held through a bank, broker or other nominee, then you are the beneficial owner of shares held in “street name,” and you must obtainwill need to submit voting instructions to the institution that holds your shares. If you do not give instructions to your broker, your broker can vote your shares only with respect to “discretionary” items, but not with respect to“non-discretionary” items.

Discretionary items are proposals considered routine under the rules on which your broker may vote shares held in street name without your voting instructions. Onnon-discretionary items for which you do not give your broker instructions, the shares will not be voted, which is referred to as a proxy, executed in your favor, from“brokernon-vote.” Please see “—What proposals will be voted on at the holderAnnual Meeting and what vote is required to approve each proposal?” below for details regarding broker voting for each proposal.

As a beneficial owner, you are invited to attend the Annual Meeting. If you are a beneficial owner and not the stockholder of record, to be able toyou may not vote your shares in person at the Annual Meeting.Meeting unless you request and obtain a valid proxy from your bank, broker or other nominee.

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of three ways:

If you are a beneficial owner ofhold your shares in street name, you must contact the bank, broker or other nominee holding your shares and follow their instructions for changing your vote.

How many votes do you need to holdWhat is the Annual Meeting?quorum requirement?

A quorum of stockholders is necessary to conduct business at the Annual Meeting. Pursuant to our amendedAmended and restated bylaws,Restated Bylaws (the “Bylaws”), a quorum will be present if a majority of the voting power of outstanding shares of the Company entitled to vote generally in the election of directors is represented in person or by proxy at the Annual Meeting. On the record date,Record Date, there were 26,338,32936,611,157 shares of common stock outstanding and entitled to vote. Thus, 13,169,16518,305,579 shares must be represented by stockholders present at the Annual Meeting or represented by proxy to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your bank, broker bank or other nominee) or if you attend the Annual Meeting and vote in person. Abstentions and broker non-votes will be counted for the purpose of determining whether a quorum is present for the transaction of business. If a quorum is not present, the chairman of the meeting or the holders of a majority of the votes present at the Annual Meeting may adjourn the Annual Meeting to another date.

What proposals will be voted on at the Annual Meeting?Meeting and what vote is required to approve each proposal?

The following table provides a description of the proposals that will be voted on at the Annual Meeting:

Plurality of Votes Cast means that, with respect to Proposal 1, the nominees for director receiving the greatest number of votes will be elected. Withheldelected and, with respect to Proposal 4, the option receiving the greatest number of votes will be recommended by stockholders to the Board. With respect to Proposal 1, withheld votes, abstentions and “broker non-votes”brokernon-votes will have no effect on the election of a nominee. With respect to Proposal 4, abstentions and brokernon-votes will have no effect on the outcome of the proposal.

Majority of Votes Castmeans that a proposal that receives an affirmative majority of the votes cast will be approved. Abstentions and brokernon-votes, if any, will not be counted “FOR”“For” or “AGAINST” this proposal“Against” Proposal 2 or Proposal 3 and will have no effect on thisthe outcome of either proposal.

Broker Discretionary Voting occurs when a We do not expect to receive broker doesnon-votes for Proposal 2, as banks, brokers and other nominees will have discretionary authority to vote shares for which beneficial owners do not receiveprovide voting instructions from the beneficial owner and votes those shares in its discretion on any proposal on which it is permitted to vote.

How are votes counted?instructions.

Votes on each proposal will be countedtabulated by the inspector of elections appointed for the meeting, who will separately count “For” and (with respect to proposals other than the election of directors) “Against” votes, abstentions and brokernon-votes. Abstentions will be counted towards the vote total for each proposal, and will have the same effect as “Against” votes. Broker non-votes, as described in the next paragraph, have no effect and will not be counted towards the vote total for Proposals 1 and 2.

If your shares are held by your broker as your nominee (that is, in “street name”), you will need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker to vote your shares. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items. Discretionary items are proposals considered routine under the rules on which your broker may vote shares held in street name without your voting instructions. Onnon-discretionary items for which you do not give your broker instructions, the shares will be treated as brokernon-votes. Under current broker voting rules, any election of a member of the Board of Directors, whether contested or uncontested, is considered“non-discretionary” and

therefore brokers are not permitted to vote your shares held in street name for the election of directors in the absence of instructions from you. Proposal 1 is“non-discretionary” and therefore if you hold your shares through a broker, bank or other agent, your shares will not be voted on Proposal 1 unless you provide voting instructions to the record holder.meeting.

Could other matters be decided at the Annual Meeting?

REGENXBIOThe Company does not know of any other matters that may be presented for action at the Annual Meeting. Should any other business come before the Annual Meeting, the personsindividuals named as proxies on the proxy card will have discretionary authority to vote the shares represented by proxies in accordance with their best judgment. If you hold shares through a bank, broker bank or other nominee, the individuals named as described above, theyproxies on the proxy card will not be able to vote your shares on any other business that comes before the Annual Meeting unless theysuch individuals receive instructions from you with respect to such other business.

What happens if a director nominee is unable to stand for election?

If a nominee is unable to stand for election, ourthe Board of Directors may either:

If ourthe Board of Directors designates a substitute nominee, shares represented by proxies voted for the nominee who is unable to stand for election will be voted for the substitute nominee.

What happens if I sign and returnsubmit my proxy card but do not provide voting instructions?

If you submit a proxy via telephone or the internet or return a signed and dated proxy card without marking any voting selections,indicating instructions with respect to a specific proposal, your shares will be voted:voted in accordance with the Board’s recommendation for such proposal.

What do I need to show to attend the Annual Meeting in person?

You will need proof of your share ownership (such as a recent brokerage statement or letter from your broker showing that you owned shares of our common stock as of April 7, 2016)the Record Date and a form of photo identification.identification, such as a valid driver’s license. If you do not have proof of ownership and valid photo identification, you may not be admitted to the Annual Meeting. If you are a stockholder of record, your ownership as of the Record Date will be verified prior to admittance into the meeting. If you are not a stockholder of record but hold shares in street name, you must provide proof of beneficial ownership as of the Record Date, such as an account statement or similar evidence of ownership.

All bags, briefcases and packages will be held at registration and will not be allowed in the meeting.Annual Meeting. We will not permit the use of cameras (including cell phones and other devices with photographic capabilities) andor other recording devices in the meeting room.

Who is paying for this proxy solicitation?

The accompanying proxy is being solicited by the Board of Directors of the Company.Board. In addition to this solicitation, directors and employees of the Company may solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting

proxies. In addition, the Company may also retain one or more third parties to aid in the solicitation of brokers, banks and institutional and other stockholders. We will pay for the entire cost of soliciting proxies. We may reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

What happens if the Annual Meeting is postponed or adjourned?

Unless the polls have closed or you have revoked your proxy, your proxy will still be in effect and may be voted once the Annual Meeting is reconvened. However, you will still be able to change or revoke your proxy with respect to any proposal until the polls have closed for voting on such proposal.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results are expected to be announced at the Annual Meeting. FinalWe expect to report final voting results will be reported onin a Current Report onForm 8-K filed with the SEC no later than the fourth business day after the Annual Meeting, or June 7, 2016.Meeting.

How can I find REGENXBIO’sthe Company’s proxy materials and Annual Report on the Internet?internet?

This proxy statementProxy Statement and the Annual Report on Form 10-K for the year ended December 31, 2015 are available at our corporate website at www.regenxbio.com. You also can obtain copies without charge at the SEC’s website at www.sec.gov. Additionally, in accordance with SEC rules, youwww.sec.gov and may access these materials at www.proxyvote.com, which doeswww.proxyvote.com. Website addresses referenced herein are intended to provide inactive, textual references only, and the information on these websites is not have “cookies” that identify visitors to the site.part of this Proxy Statement.

How do I obtain a separate set of REGENXBIO’sthe Company’s proxy materials if I share an address with other stockholders?

In some cases, stockholders holding their shares in a brokerage or bank account who share the same surname and address receive only one copy of the Notice. This practice, called “housekeeping,“householding,” is designed to reduce duplicate mailings and save printing and postage costs as well as natural resources. If you would like to have a separate copy of the Notice, or ourthe Annual Report on Form 10-K and/or proxy statementthis Proxy Statement mailed to you or to receive separate copies of future mailings, please submit your request to the address or phone number that appears on your Notice or proxy card. We will deliver such additional copies promptly upon receipt of such request.

In other cases, stockholders receiving multiple copies of proxy materials at the same address may wish to receive only one.one copy. If you would like to receive only one copy, if you now receive more than one, please submit your request to the address or phone number that appears on your Notice or proxy card.

Can I receive future proxy materials and annual reports electronically?

Yes. This proxy statementProxy Statement and the Annual Report on Form 10-K for the year ended December 31, 2015 are available on our investor relations website located at http://ir.regenxbio.com.www.regenxbio.com. Instead of receiving paper copies in the mail, stockholders can elect to receive an emaile-mail that provides a link to our future annual reports and proxy materials on the internet. OptingIf you opt to receive your proxy materials electronically, you will receive an automatic link to the proxy voting site. In addition, electing to receive your proxy materials electronically will save us the cost of producing and mailing documents to your home or business willand reduce the environmental impact of our annual meetings and will give you an automatic link to the proxy voting site.of stockholders.

May I propose actions for consideration at next year’s annual meeting of stockholders or nominate individuals to serve as directors?

Yes. The following requirements apply to stockholder proposals, including director nominations, for the 2017our 2020 annual meeting of stockholders.stockholders:

Requirements for Stockholder Proposals to beBe Considered for Inclusion in REGENXBIO’sthe Company’s Proxy Materials:Materials

Stockholders interested in submitting a proposal (other than the nomination of directors) for inclusion in the proxy materials to be distributed by us for the 2017our 2020 annual meeting of stockholders may do so by following the procedures prescribed inRule 14a-8 of promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act)“Exchange Act”). To be eligible for inclusion in REGENXBIO’sthe Company’s proxy materials, stockholder proposals must be received at our principal executive offices no later than the close of business on December 19, 201613, 2019, which is the 120^th120th day prior to the first anniversary of the date that we released this proxy statementProxy Statement to our stockholders for the Annual Meeting. To be included in our proxy materials, your proposal also must comply with the Company’s amendedour Bylaws and restated bylaws and Rule 14a-8 promulgated under the Exchange Act regarding the inclusion of stockholder proposals in company-sponsored proxy materials. If we change the date of the 2017our 2020 annual meeting of stockholders by more than 30 days from the anniversary of this year’s Annual Meeting, stockholder proposals must be received a reasonable time before we begin to print and mail our proxy materials for the 2017our 2020 annual meeting of stockholders. ProposalsSuch proposals should be sent to REGENXBIO Inc., 9712 Medical Center Drive,9600 Blackwell Road, Suite 100,210, Rockville, MDMaryland 20850, Attn:Attention: Corporate Secretary.

Requirements for Stockholder Nomination of Director Candidates and Stockholder Proposals Not Intended for Inclusion in REGENXBIO’sthe Company’s Proxy Materials:Materials

Stockholders who wish to nominate persons for election to the Board of Directors at the 2017our 2020 annual meeting of stockholders or who wish to present a proposal at the 2017our 2020 annual meeting of stockholders, but who do not intend for such proposal to be included in REGENXBIO’sthe Company’s proxy materials for such meeting, must deliver written notice of the nomination or proposal to our Corporate Secretary at 9712 Medical Center Drive, Suite 100, Rockville, MD 20850our principal executive offices no earlier than February 1, 2017January 27, 2020, which is the 75th day prior to the first anniversary of the date we released this Proxy Statement to our stockholders for the Annual Meeting, and no later than March 3, 2017.February 26, 2020, which is the 45th day prior to the first anniversary of the date we released this Proxy Statement to our stockholders for the Annual Meeting. However, if we change the 2017date of our 2020 annual meeting of stockholders is held earlierby more than May 2, 2017 or later than July 1, 2017,30 days from the anniversary of this year’s Annual Meeting, such nominations and proposals must be received no later than the close of business on the later of (a) the 90^th90th day prior to the 2017our 2020 annual meeting of stockholders and (b) the 10th day following the day we first publicly announce the date of the 2017our 2020 annual meeting.meeting of stockholders. The stockholder’s written notice must include certain information concerning the stockholder and each nominee and proposal, as specified in our amendedBylaws. If the stockholder does not also satisfy the requirements ofRule 14a-4 promulgated under the Exchange Act, the persons named as proxies will be allowed to use their discretionary voting authority when and restated bylaws.if the matter is raised at the 2020 annual meeting of stockholders. Such nominations or proposals should be sent to REGENXBIO Inc., 9600 Blackwell Road, Suite 210, Rockville, Maryland 20850, Attention: Corporate Secretary.

Copy of Amended and Restated Bylaws:Bylaws

You may request a copy of the Company’s amended and restated bylawsour Bylaws to be delivered to you at no charge by writing to REGENXBIO’sthe Company’s Corporate Secretary at 9712 Medical Center Drive, Suite 100, Rockville, MD 20850.

Whom should I call if I have any questions?

If you have any questions, would like additional REGENXBIO proxy materials or proxy cards, or need assistance in voting your shares, please contact Investor Relations, REGENXBIO Inc., 9712 Medical Center Drive,9600 Blackwell Road, Suite 100,210, Rockville, MDMaryland 20850, or by telephone at (240) 552-8181.

Important Notice Regarding the AvailabilityAttention: Corporate Secretary. In addition, we have filed a copy of Proxy Materials

for the Meetingour Bylaws as Exhibit 3.2 to be Held on Wednesday, June 1, 2016

This proxy statement and our AnnualCurrent Report on Form 10-K are available on-line8-K filed on September 22, 2015, which may be accessed without charge on our website atwww.proxyvote.com. www.regenxbio.com and the SEC’s website at www.sec.gov.

PROPOSAL 11:

ELECTION OF ALLAN M. FOX AND CAMILLE SAMUELS AS CLASS I DIRECTORS

Under our amended and restated bylaws, ourBylaws, the Board of Directors is divided into three classes of roughly equal size. The members of each class are elected to serve a 3-yearthree-year term with the term of office of each of the three classes ending in successive years. Pursuant to our amended and restated bylaws,Bylaws, the Board of Directors has fixed the current number of directors at eight, but the number of directors will be seven following the expiration of Edgar G. Engleman, M.D.’s term at the Annual Meeting. Edgar G. Engleman, M.D.,nine. Daniel J Abdun-Nabi, Allan M. Fox and Camille SamuelsAlexandra Glucksmann, Ph.D., are the three Class I directors whose terms expire at this Annual Meeting. On March 1, 2016, Dr. Engleman informed theThe Board of Directors that he would not stand for re-election at the Annual Meeting. Mr.has nominated Messrs. Abdun-Nabi and Fox and Ms. Samuels have been nominated for election by our Board of DirectorsDr. Glucksmann (collectively, the “nominees” and each, a “nominee”) to serve until the 20192022 annual meeting of stockholders or until their successors are elected, (oror until their earlier death, resignation or removal). It is our policy to encourage nominees for director to attend the Annual Meeting.

Directors are elected by a pluralityremoval. Each of the votes cast atnominees was recommended for election by the Annual Meeting. The two nominees receivingNominating and Corporate Governance Committee, and each such recommendation was approved unanimously by the highest number of “FOR” votes will be elected. Abstentions and broker non-votes will have no effect on the outcome of the election of directors at the Annual Meeting.Board.

Shares represented by signed proxy cards will be voted on Proposal 1 “FOR”“For” the election of Mr.Messrs. Abdun-Nabi and Fox and Ms. SamuelsDr. Glucksmann to the Board of Directors at the Annual Meeting, unless otherwise marked on the card. If any REGENXBIO director nomineeof the nominees becomes unavailable for election as a result of an unexpected occurrence, shares represented by proxy will be voted for the election of a substitute nominee designated by ourthe current Board, of Directors, unless otherwise marked on the card. Mr.Messrs. Abdun-Nabi and Fox and Ms. Samuels, REGENXBIO’s two director nominees,Dr. Glucksmann have each agreed to serve as a director if elected. We have no reason to believe that eitherany of the REGENXBIO nominees will be unable to serve if elected.

Nominees for Election as Class I Directors at the Annual Meeting

This year’s nominees for election to the Board of Directors as our Class I directors to serve for a term of three years expiring at the 2019 annual meeting of stockholders, or until their successors have been duly elected and qualified or until their earlier death, resignation or removal, are provided below. The age of each director as of April 18, 2016 is set forth below.

The following is additionalCertain information about each of the nominees as of the date of this proxy statement,is furnished below, including their business experience, public company director positions held currently or at any time during the last five years involvement in certain legal or administrative proceedings, if applicable, and the experiences,experience, qualifications, attributes or skills that caused the Nominating and Corporate Governance Committee and ourthe Board of Directors to determine that the nominees should continue to serve as onedirectors.

Daniel J. Abdun-Nabi has been a Director since August 2016. Mr. Abdun-Nabi served as the Chief Executive Officer of our directors.Emergent BioSolutions Inc. (“Emergent”), a publicly held biopharmaceutical company, from March 2018 until his retirement in March 2019, as the President and Chief Executive Officer of Emergent from April 2012 to March 2018 and as the President and Chief Operating Officer of Emergent from May 2007 to March 2012, and he held various other senior management positions at Emergent beginning in 2004. Mr. Abdun-Nabi previously served as General Counsel for IGEN International, Inc. (“IGEN”), a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a vaccine developer and manufacturer. Mr. Abdun-Nabi has served as a director at Aptevo Therapeutics Inc., a publicly held biotechnology company, since August 2016. He served as a director at Emergent from May 2009 to March 2019. Mr. Abdun-Nabi received an LL.M. in Taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. from the University of Massachusetts, Amherst. Mr. Abdun-Nabi’s qualifications to continue to serve as a member of the Board include his extensive experience in senior management positions at publicly held biopharmaceutical companies, his current and prior service on the boards of such companies and his demonstrated business judgment.

Allan M. Foxhas been a Director since February 2009. Mr. Fox is the founding partner of FoxKiser,FOXKISER LLP (“FOXKISER”), a nationally recognized firm committed to the strategic development of transformative innovations from biomedical research, which was formed in September 1986. Mr. Fox specializes in identifying business opportunities and improving competitive market positions. HeThrough FOXKISER, he has participated in the formation and development of numerous ventures in the public and private sectors.sectors, including the founding of REGENXBIO and Dimension Therapeutics, Inc. Before forming FoxKiser,FOXKISER, Mr. Foxco-led the establishment of the Washington

office of the law firm of Kaye Scholer. While in the public sector, Mr. Fox served as Chief of Staff and Chief Legislative Assistant to U.S. Senator Jacob K. Javits of New York. He also served as Chief Counsel to the United States Senate Health and Scientific Research Subcommittee, chaired by Senator Edward M. Kennedy. Mr. Fox has served as a director at WindMIL Therapeutics, Inc., a privately held biotechnology company, since March 2017. Mr. Fox was a Fellow in Law, Science and Medicine at Yale Law School where he received an LL.M. degree. Mr. Fox also holds a J.D. and B.A. from Temple University. Mr. Fox has specific

attributes that qualify him to continue to serve as a member of ourthe Board, of Directors, including his broad experience in providing strategic advice to and investing in biotechnology companies throughout their life cycles, his expertise in identifying business opportunities, his deep experience with REGENXBIO since the biotechnology sectortime of its founding and FDA consulting, as well as his current and prior service on private company boards.boards of directors.

Camille SamuelsAlexandra Glucksmann, Ph.D., has been a Director since January 2015. Ms. SamuelsMay 2018. Dr. Glucksmann has beenserved as the President and Chief Executive Officer of Cedilla Therapeutics, Inc., a Partnerprivately held biotechnology company, since April 2018. From October 2017 to March 2018, Dr. Glucksmann was anEntrepreneur-in-Residence at Venrock,Third Rock Ventures, LLC, a privately held healthcare venture capital firm, since May 2014.where she focused on company formation. She was also a founding employee of Editas Medicine, Inc., a publicly held biotechnology company, and served as its Chief Operating Officer from October 2013 to March 2017. Prior to Venrock, Ms. Samuels spent overthat, Dr. Glucksmann was a decadefounding employee of Cerulean Pharma Inc., a publicly held biotechnology company, and served as a Managing Director at Versant Ventures, a life sciences venture capital firm, which she joined in 2000its Senior Vice President of research and for which she provided services through March 2014. Ms. Samuels currently serves on the board of Spirox Corporation and Unity Biosciences, Inc. She previouslybusiness operations from September 2006 to June 2013. Dr. Glucksmann has served as a board member ordirector at Scenic Biotech BV, a board observer on other healthcare companies including Achaogen, Inc., Fluidigm Sciences Inc., Genomic Health, Inc., Novacardia, Inc. (acquired by Merck & Co., Inc.), ParAllele BioScience, Inc. (acquired by Affymetrix Inc.), and Syrrx Inc. (acquired by Takeda Pharmaceutical Co.). Priorprivately held biotechnology company, since September 2017. From August 2006 to her venture career, Ms. Samuels held business development and strategic marketing roles at Tularik Inc. (acquired by Amgen Inc.) and Genzyme Corporation (acquired by Sanofi-Aventis SA). She also workedMay 2015, she served as a management consultant to consumer, healthcaredirector at Taconic Biosciences, Inc. Dr. Glucksmann received a B.S. in Bacteriology from the University of Wisconsin-Madison and biotech companies at LEK Consulting. Ms. Samuels holds a B.A.Ph.D. in Molecular Genetics and Cell Biology from Dukethe University of Chicago, and an M.B.A. from Harvard Business School. Ms. Samuels has specific attributes that qualifyshe completed her postdoctoral fellowship at the Massachusetts Institute of Technology. Dr. Glucksmann’s qualifications to continue to serve as a member of ourthe Board of Directors, includinginclude her extensive experience in senior management positions at biotechnology companies, particularly her experience in venture capital investingthe formation and indevelopment of biotechnology companies.

Vote Required

Directors are elected by a plurality of the biotechnology sector, as well as her prior servicevotes cast at the Annual Meeting. The three nominees receiving the highest number of “For” votes will be elected. Abstentions and brokernon-votes will have no effect on public and private company boards and audit committees.the outcome of the election of directors at the Annual Meeting.

YOURRecommendation of the Board

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOUA VOTE THE PROXY CARD “FOR” THE ELECTION OF ALLAN M. FOX AND CAMILLE SAMUELS AS CLASS I DIRECTORSEACH DIRECTOR NOMINEE.

Continuing Directors Not Standing for Election

Certain information about those directors whose terms do not expire at the Annual Meeting is furnished below, including their business experience, public company director positions held currently or at any time during the last five years involvement in certain legal or administrative proceedings, if applicable, and the experiences, qualifications, attributes or skills that caused the Nominating and Corporate Governance Committee and ourthe Board of Directors to determine that the directors should serve as one of our directors. The ageterm of each director asthe Class II directors will expire at the 2020 annual meeting of April 18, 2016 is set forth below.stockholders, and the term of the Class III directors will expire at the 2021 annual meeting of stockholders.

Class II Directors (Terms Expire in 2017)2020)

Donald J. Hayden, Jr. has been a Director and the Chairman of ourthe Board of Directors since February 2013. From 1991 to 2006, Mr. Hayden held several executive positions with Bristol-Myers Squibb Company, a biopharmaceutical company, most recently serving as Executive Vice President and President, Americas. Mr. Hayden is currently a member and chairmanserved as Chairman of the Boardboard of Directors ofdirectors at Insmed Incorporated (“Insmed”), a publicly held biopharmaceutical company, from December 2010 to November 2018 and Vitae Pharmaceuticals Inc. He is also lead independenthe currently serves as a director at AmicusInsmed. He also has served as Chairman of the board of directors at WindMIL Therapeutics, Inc., a member of the Board of Directorsprivately held biotechnology company, since January 2017 and as a director at Otsuka America Pharmaceutical, Inc., and serves as a senior advisor to Prospect Venture Partners, a leading life sciences venture capital firm.privately held U.S. subsidiary of Otsuka Pharmaceutical Co., Ltd., since January 2010. Mr. Hayden served as Lead Independent Director at Amicus Therapeutics, Inc. (“Amicus”) from February 2010 to October 2018, director at Amicus from March 2006 to October 2018, Chairman of the board of directors at Vitae Pharmaceuticals, Inc. from March 2006 to October 2016, and as a director ofat Dimension Therapeutics, Inc., from October 2013 to July 2015. Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. Mr. Hayden has specific attributes that qualify him to continue to serve as a member of ourthe Board, of Directors, including his broad experience in the biotechnology and pharmaceutical industries, as well asindustry, his prior service onchairing public and private company boards, his experience helping shape new technologies, products and markets and his executive-level service at a number of publicexperience leading health care businesses in the United States and private companies.internationally.

A.N. “Jerry” Karabelas, Ph.D., has been a Director since May 2015. Since December 2001, Mr.Dr. Karabelas has been a managing memberPartner at Care Capital, II, LLC and(“Care Capital”), a life sciences venture firm, since December 2001. Prior to joining Care Capital, III, LLC (Care Capital), a provider of capital for entrepreneurial private and public companies developing pharmaceuticals. Prior to his work at Care Capital, from July 2000 to September 2001, Mr.Dr. Karabelas was Chairman at Novartis BioVentures Fund, which is owned by Novartis AG (Novartis)(“Novartis”), a provider of capital for life sciences companies across the biotech, medical devices and diagnostics industries, prior to which Mr. Karabelashe was the Chief Executive Officer of Novartis Pharma AG, which is also owned by Novartis. Before joining Novartis, Dr. Karabelas was Executive Vice President, Worldwide Pharmaceuticals of SmithKline Beecham, where he was responsible for U.S. and European operations, regulatory and strategic marketing. Dr. Karabelas has served as a director at Bausch Health Companies Inc., a publicly held specialty pharmaceutical and medical device company, since June 2016, a director at Braeburn Pharmaceuticals, Inc., a privately held pharmaceutical company, since September 2015 and Chairman of the board of directors at Polyphor AG, a privately held pharmaceutical company, since June 2013. He served as Chairman of the board of directors at Inotek Pharmaceuticals Corporation from July 2012 to June 2016. In connection with his work at Care Capital, Mr.Dr. Karabelas haspreviously served on numerous boards of directors of pharmaceutical and therapeutics companies, including Renovo, plc, Vanda Pharmaceuticals, Inc. and NitroMed, Inc. Since June 2013, Mr.Dr. Karabelas hasalso previously served as Chairman of Polyphor AG. Mr. Karabelas also served as a member of the boardsboard of directors ofat SkyePharma, plc from May 2001 to May 2009 and Human Genome Sciences. Mr.Dr. Karabelas received a B.S. from the University of New Hampshire and a Ph.D. from the Massachusetts College of Pharmacy. Mr.Dr. Karabelas has specific attributes that qualify him to continue to serve as a member of ourthe Board, of Directors, including his extensive experience in working withsenior management positions at biopharmaceutical companies, his strong knowledge of strategic and regulatory issues, his insight into international operations and his international perspective on the life sciences industry and healthcare related issues.

DanielTassé has been a Director since August 2016. Mr. Tassé has served as the Chief Executive Officer of DBV Technologies SA, a publicly held pharmaceuticals companies, advising developingbiopharmaceutical company, since November 2018. From March 2016 to March 2019, he was the Chairman of Alcresta Therapeutics, Inc. (“Alcresta”), a privately held biopharmaceutical company, and from March 2016 to November 2018, he was the Chairman and Chief Executive Officer of Alcresta. Mr. Tassé has served as a director at Indivior PLC (where he is the Lead Independent Director), a London Stock Exchange publicly traded pharmaceutical company, since August 2014. Additionally, he has served as a director at Bellerophon Therapeutics, Inc. (“Bellerophon”), a publicly held biopharmaceutical company, since December 2013, HLS Therapeutics Inc. (“HLS”), a Toronto Stock Exchange publicly traded pharmaceutical company, since March 2018, and BioQ Pharma (“BioQ”), a privately held pharmaceutical company, since December 2014, but Mr. Tasse does not expect to stand forre-election at Bellerophon, HLS or BioQ in 2019. Prior to the acquisition of Ikaria Inc. (“Ikaria”) by Mallinckrodt Pharmaceuticals in April 2015, Mr. Tassé was President, Chief Executive Officer and Chairman of Ikaria and served as the Interim Chief

Executive Officer and President of Bellerophon from February 2014 to June 2014. Previously, Mr. Tassé was the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. and Vice President and Regional Director for Australasia at GlaxoSmithKline plc. Mr. Tassé was a member of the Health Section Governing Board of the Biotechnology Industry Organization, where he participated on the bioethics, regulatory environment and reimbursement committees. Additionally, Mr. Tassé was a member of the board of directors of the Pharmaceutical Research and Manufacturers of America, where he participated on the FDA and biomedical research committee. Mr. Tassé received a B.Sc. in Biochemistry from the University of Montreal. Mr. Tassé has specific attributes that qualify him to continue to serve as a member of the Board, including his extensive track record of business building in the healthcare industry, his strong background within critical care, his global management experience and his detailed knowledge of the life sciences therapeutics and pharmaceuticals companies and his executive leadership, managerial and business experience.industry.

Class III Directors (Terms Expire in 2018)2021)

Luke M. Beshar has been a Director since April 2015. Mr. Beshar was the Executive/Senior Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical company from November 2007 to February 2015. He is a former Chief Financial Officer of various public and private companies and has more than 30 years of general and financial management experience. Mr. Beshar served as the Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc. from November 2007 to February 2015 and as Executive Vice President and Chief Financial Officer of Cambrex Corporation, a life sciences company, from December 2002 to November 2007, a global life sciences company, and previously as Senior Vice President and Chief Financial Officer at Dendrite International, a leading provider of services to the life sciences industry.2007. Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a Certified Public Accountant. Mr. Beshar ishas served as a Directordirector and chair of the audit committee at Trillium Therapeutics Inc. and Chair of its Audit Committee,, a Director and member of the Audit Committee of Sancilio Pharmaceuticals Company, Inc.,publicly held immuno-oncology company, since March 2014, and a Director of EnteraBio Ltd.director at Artara Therapeutics, a privately held company focused on rare diseases, since October 2018. Mr. Beshar holds a B.S. degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia. Mr. Beshar has specific attributes that qualify himBeshar’s qualifications to continue to serve as a member of ourthe Board of Directors, includinginclude his financial and managerial experience in the biotechnology and medicallife sciences industries, including serving as Chief Financial Officer, his financial and accounting expertise as well asand his prior service on public and private company boards.

Kenneth T. Mills has been our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FoxKiser,FOXKISER, most recently as a partner,Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately-held life sciences company, from January 2004 to December 2006 and was part of the original management team that established the company’s operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, International, a medical diagnosticsbiotechnology company, where he served as Director of Business Development up through the company’s acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. We believe that Mr. Mills’ qualifications to continue to serve as a directormember of our companythe Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a senior-level executive in both early stage and mature biotechnology companies.companies and his demonstrated business judgment.

David C. Stump, M.D., has been a Director since October 2015. From November 1999 to December 2012, Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from May 2007 to December 2012, Executive Vice President, Drug Development from December 2003 to May 2007 and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999, including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump ishas served as a member of the boardboards of directors ofat Sunesis Pharmaceuticals, Inc.,

since June 2006, MacroGenics, Inc. since September 2013 and Portola Pharmaceuticals, Inc. andsince September 2015, each of which is a member ofpublicly held biopharmaceutical company. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served on the board of directors ofas a director at Dendreon Corporation.Corporation, a biotechnology company, from June 2010 to June 2015. Dr. Stump holds an A.B. from

Earlham College and an M.D. from Indiana University and didcompleted his residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa. Dr. Stump has specific attributes that qualify him to continue to serve as a member of ourthe Board, of Directors, including his substantial medical and scientific background and clinical expertise, his extensive experience in research and development and operations in the biotechnology industry background, as well asand his prior service on public company boards.

CORPORATE GOVERNANCE

IndependenceOur Board is responsible for oversight of the management of the Company. In carrying out its responsibilities, the Board selects and monitors our management team, provides oversight of our financial reporting processes and determines and implements our corporate governance policies.

Corporate Governance Guidelines

The Board has adopted corporate governance guidelines, which, along with the Company’s restated certificate of incorporation and Bylaws, and the charters of the committees of the Board, provide the framework for the governance of Directorsthe Company. Our current corporate governance guidelines can be found, together with other corporate governance information, in the corporate governance section of our corporate website at www.regenxbio.com. The Board also evaluates the charters of its committees from time to time, as appropriate.

Code of Business Conduct

We maintain a code of business conduct that qualifies as a “code of ethics” under Item 406 of the SEC’sRegulation S-K and applies to each of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions. The code of business conduct addresses various topics, including: (1) compliance with applicable laws, rules and regulations; (2) conflicts of interest; (3) public disclosure of information; (4) insider trading; (5) corporate opportunities; (6) competition and fair dealing; (7) gifts; (8) discrimination, harassment and retaliation; (9) health and safety; (10) record-keeping; (11) confidentiality; (12) protection and proper use of company assets; (13) payments to government personnel; and (14) the reporting of illegal and unethical behavior.

The code of business conduct is available in the corporate governance section of our corporate website at www.regenxbio.com. Any amendment or waiver of the “code of ethics” provisions of the code of business conduct for an executive officer or director may be granted only by the Board or a committee thereof and must be timely disclosed as required by applicable law. We intend to satisfy the disclosure requirements regarding any such amendment or waiver applicable to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in a report filed with the SEC onForm 8-K or on our corporate website at www.regenxbio.com.

Director Independence

As required under NASDAQNasdaq listing standards, a majority of the members of a listed company’s board of directors must qualify as “independent,” as affirmatively determined by the board of directors. Consistent with these regulations, after review of all relevant transactions or relationships between each director, or any of hissuch director’s family members, and the Company, its senior management and its independent registered public accounting firm, the Board of Directors has determined that all of our directors are independent directors within the meaning of applicable NASDAQNasdaq listing standards, except for Mr.Kenneth T. Mills, our Chief Executive Officer,President and CEO, and Allan M. Fox and Donald J. Hayden, Jr. Our Board of Directors currently expects that Donald Hayden, Jr. will qualify as an independent director in accordance with the rules of NASDAQ commencing during the fourth quarter of 2016.Fox.

Information Regarding the Board of Directors and its Committees

As required under NASDAQNasdaq listing standards, our independent directors meet in regularly scheduled executive sessions at which only independent directors are present, noting that we have relied on Nasdaq Marketplace Rule 5615(b)(1), a “phase-in” rule for companies following their initial public offerings, in allowing Donald J. Hayden, Jr., Chairman of thepresent.

The Board of Directors, to be present and preside over these executive sessions.

Our Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for each of the Board committees during 2015:2018:

Below is a description of each committee of the Board of Directors.Board. The Board of Directors has determined that each member of the Audit, Compensation and Nominating and Corporate Governance Committees meets applicable rules and regulations regarding “independence” and that each such member is free of any relationship that would interfere with his individual exercise of independent judgment with regard to the Company.

Audit Committee

The Audit Committee of the Board of Directors oversees the quality and integrity of the Company’s financial statements and other financial information provided to the Company’s stockholders, the retention and performance of the Company’s independent accountants, the effectiveness of the Company’s internal controls and disclosure controls, and the Company’s compliance with ethics policies and SEC and related regulatory requirements. Pursuant to the Audit Committee charter, the functions of the Audit Committee include, among other things: (1) appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; (2) overseeing the work of our registered public accounting firm, including through the

receipt and consideration of reports from such firm; (3) reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures; (4) monitoring our internal control over financial reporting and our disclosure controls and procedures; (5) meeting independently with our registered public accounting firm and management; (6) furnishing the audit committee report required by SEC rules; (7) reviewing and approving or ratifying any related person transactions; and (8) overseeing our risk assessment and risk management policies. Our Audit Committee charter can be found in the corporate governance section of our corporate website at www.regenxbio.com.

Three directors comprised the Audit Committee as of December 31, 2015:2018: Mr. Beshar (the Chairman of the Audit Committee), Mr. Abdun-Nabi and Dr. Stump and Ms. Samuels.Stump. The Audit Committee met fourseven times during 2015. Effective October 14, 2015, Dr. Stump became a member of the Audit Committee and Mr. Hayden resigned as a member of the Audit Committee.2018.

All members of our Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and NASDAQ. OurNasdaq. The Board of Directors has determined that Mr.each of Messrs. Abdun-Nabi and Beshar is an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable NASDAQ rules and regulations.Nasdaq listing standards.

The Board of Directors annually reviews the NASDAQNasdaq listing standards definition of independence for Audit Committee members and has determined that all members of our Audit Committee are independent (as independence is currently defined in applicable NASDAQNasdaq listing standards andRule 10A-3 promulgated under the Exchange Act).

Compensation Committee

The Compensation Committee of the Board of Directors reviews and approves the design of, assesses the effectiveness of, and administers executive compensation programs for officers and employees, including our equity incentive plans. Pursuant to the Compensation Committee charter, the functions of the Compensation Committee include:include, among other things: (1) evaluating the performance of our chief executive officerCEO and determining the chief executive officer’sCEO’s salary and

contingent compensation based on his or her performance and other relevant criteria; (2) identifying the corporate and individual objectives governing the chief executive officer’sCEO’s compensation; (3) approving the compensation of our other executive officers; (4) making recommendations to our boardthe Board with respect to director compensation; (5) reviewing and approving the terms of material agreements between us and our executive officers; (6) overseeing and administering our equity incentive plans and employee benefit plans; (7) reviewing and approving policies and procedures relating to the perquisites and expense accounts of our executive officers; (8) preparing the annual Compensation Committee report required by SEC rules; and (9) conducting a review of executive officer succession planning, as necessary, reporting its findings and recommendations to ourthe Board, of Directors, and working with the Board in evaluating potential successors to executive officer positions. In accordance with NASDAQNasdaq listing standards and our amended and restated Compensation Committee charter, ourthe Board of Directors has granted our Compensation Committee the authority and responsibility to retain or obtain the advice of compensation consultants, legal counsel and other compensation advisers, the authority to fund such advisers, and the responsibility to consider the independence factors specified under applicable law and any additional factors the Compensation Committee deems relevant. Our Compensation Committee charter can be found in the corporate governance section of our website at www.regenxbio.com.

Three directors comprised the Compensation Committee of the Board of Directors as of December 31, 2015:2018: Mr. Hayden (the Chairman of the Compensation Committee), Mr. Beshar and Ms. Samuels.Mr. Tassé. The Compensation Committee met threeseven times during 2015.2018.

The Board of Directors has determined that all members of the Compensation Committee are independent (as independence is currently defined in the NASDAQNasdaq listing standards) other than Mr. Hayden. However, we

are permitted to phase-in our compliance with the independent compensation committee requirements set forth in the rules of NASDAQ and the Exchange Act, which would require the compensation committee to be compromised of all independent members within one year of listing. We expect that, within one year of our listing on NASDAQ, Mr. Hayden will have resigned from our compensation committee. At such time, we may appoint an independent director (as determined under the listing standards of NASDAQ and Exchange Act rules) to our compensation committee or have two directors serve on the committee. Our Board of Directors currently expects that Mr. Hayden will qualify as an independent director in accordance with the rules of NASDAQ commencing during the fourth quarter of 2016.. In addition, each of our directors serving on our Compensation Committee satisfies the heightened independence standards for members of a compensation committee under NASDAQNasdaq listing standards, each member of this committee is anon-employee director, as defined pursuant toRule 16b-3 promulgated under the Exchange Act, and is an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended (the Code)“Code”).

Our Chief Executive OfficerPresident and CEO often participates in the Compensation Committee’s meetings. He does not participate in the determination of his own compensation or the compensation of directors. However, Mr. Millsour President and CEO does make recommendations to the Compensation Committee regarding the amount and form of the compensation of the other executive officers and key employees, and he often participates in the Compensation Committee’s deliberations about their compensation. No other executive officersthe compensation of such individuals. Our Senior Vice President, Human Resources and our Senior Vice President, General Counsel also regularly participate in the Compensation Committee’s meetings, but they do not participate in the determination of the amount or form of the compensation of executive officers or directors.

The Compensation Committee has retained Radford, a compensation consulting firm, sincefrom May 2015.2015 to March 2019. In February 2016, Radford presented a new executiveconnection with the 2018 compensation report topaid by the Compensation Committee.Company, Radford provided the Compensation Committee with data about the compensation paid by our peer group of companies and other employers who compete with the Company for executives, updated the Compensation Committee on new developments in areas that fall within the Compensation Committee’s jurisdiction and was available to advise the Compensation Committee regarding all of its responsibilities. Since April 2019, the Compensation Committee has retained Willis Towers Watson, a compensation consulting firm. The compensation consultant serves at the pleasure of the Compensation Committee rather than the Company, and the consultant’s fees are approved by the Compensation Committee. In February 2016, ourThe Compensation Committee assessed the independence of each of Radford and Willis Towers Watson pursuant to applicable SEC rules and NASDAQNasdaq listing standards and concluded that thetheir work of Radford hasdid not raisedraise any conflict of interest.

Compensation Committee Interlocks and Insider Participation

None of the members of the Compensation Committee is or has ever been an officer or employee of the Company. No executive officer of the Company serves as a member of the Board of Directors or compensation committee of any other entity that has one or more executive officers serving as a member of our Board of Directors or our Compensation Committee.

Nominating and Corporate Governance Committee

OurThe Nominating and Corporate Governance Committee of the Board identifies, evaluates and recommends nominees to ourthe Board of Directors and committees of ourthe Board, of Directors, conducts searches for appropriate directors, and evaluates the performance of ourthe Board of Directors and of individual directors. Pursuant to the Nominating and Corporate Governance

Committee charter, the functions of the Nominating and Corporate Governance Committee include, among other things: (1) identifying, evaluating, and making recommendations to ourthe Board of Directors and our stockholders concerning nominees for election to our board,the Board, to each of the board’sBoard’s committees and as committee chairs; (2) annually reviewing the performance and effectiveness of our boardthe Board and developing and overseeing a performance evaluation process; (3) annually evaluating the performance of management, the boardBoard and each boardBoard committee against their duties and responsibilities relating to corporate governance; (4) annually evaluating adequacy of our corporate governance structure, policies, and procedures; and (5) providing reports to our boardthe Board regarding the committee’sNominating and Corporate Governance Committee’s nominations for election to the Board of Directors and its committees. Our Nominating and Corporate Governance Committee charter can be found in the corporate governance section of our website at www.regenxbio.com.

ThreeTwo directors comprised the Nominating and Corporate Governance Committee as of December 31, 2015:2018: Dr. Karabelas (the Chairman of the Nominating and Corporate Governance Committee), Dr. Engleman and Dr. Stump. Dr. Engleman has informed the Board of Directors that he will not stand for re-election and his term will expire on June 1, 2016 at the Annual Meeting. Following such time, the Nominating and Corporate Governance Committee will be comprised of two directors. The Nominating and Corporate Governance Committee met twofour times during 2015.2018.

The Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including being able to read and understand basic financial statements and having a general understanding of the Company’s industry. The Nominating and Corporate Governance Committee also considers other factors it deems appropriate, including, but not limited to:

In conducting this assessment, the committeeNominating and Corporate Governance Committee also considers diversity, age, skills, and such other factors as it deems appropriate given the then-current needs of the Board of Directors and the Company, to maintain a balance of knowledge, experience and capability. While diversity and variety of experiences and viewpoints represented on the Board of Directors should always be considered, the Nominating and Corporate Governance Committee believes that a director nominee should not be chosen nor excluded solely or largely because of race, color, gender, national origin or sexual orientation or identity.

In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews such directors’ overall service to the Company during their term, including the number of meetings attended, level of participation, quality of performance, and any other relationships and transactions that might impair such directors’ independence.

When there is a vacancy on the Board of Directors, the Nominating and Corporate Governance Committee uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems it appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board of Directors. The Nominating and Corporate Governance Committee meets to discuss and consider such candidates’ qualifications and then selects a nominee for recommendation to the Board of Directors by majority vote.

The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders and evaluate them using the same criteria as candidates identified by the Board of Directors or the Nominating and Corporate Governance Committee for consideration. If a stockholder of the Company wishes to recommend a director candidate for consideration by the Nominating and Corporate Governance Committee, the

stockholder recommendation should be delivered to the Corporate Secretary of the Company at the principal executive offices of the Company pursuant to the terms and conditions of our amended and restated bylaws. The stockholder recommendation must, among other things, set forth:

In addition, our amended and restated bylaws require that the stockholder recommendation shall set forth as to each person whom the stockholder proposes to nominate for election or reelection as a director (1) the name, age, business address and residence address of the person; (2) the principal occupation or employment of the

person; (3) the class, series and number of shares of capital stock of the Company that are owned beneficially and of record by the person; (4) a statement as to the person’s citizenship; (5) the completed and signed representation and agreement described above; (6) any other information relating to the person that is required to be disclosed in solicitations for proxies for election of directors pursuant to Section 14 of the Exchange Act; (7) such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected; and (8) whether and the extent to which any derivative instrument, swap, option, warrant, short interest, hedge or profit interest or other transaction has been entered into by or on behalf of such person with respect to stock of the Company and whether any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock) has been made by or on behalf of such person, the effect or intent of any of the foregoing being to mitigate loss to, or to manage risk of stock price changes for, such person or to increase or decrease the voting power or pecuniary or economic interest of such person with respect to stock of the Company.

We believe that each of our directors and nominees brings a strong background and set of skills to our Board, of Directors, giving the Board, of Directors, as a whole, an appropriate balance of thediversity, knowledge, experience, attributes, skills and expertise. In addition, fourseven of our seven continuingnine directors are independent under NASDAQNasdaq standards (Mr. Mills, our Chief Executive Officer, Allan M.President and CEO, and Mr. Fox and Donald J. Hayden, Jr. being the exceptions) and our Nominating and Corporate Governance Committee believes that all seven continuingnine directors are independent of the influence of any particular stockholder or group of stockholders whose interests may diverge from the interests of our stockholders as a whole. We believe that our directors have a broad range of personal characteristics including leadership, management, pharmaceutical, gene therapy business, marketing and financial experience and abilities to act with integrity, with sound judgment and collegially, to consider strategic proposals, to assist with the development of our strategic plan and oversee its

implementation, to oversee our risk management efforts and executive compensation and to provide leadership, to commit the requisite time for preparation and attendance at boardBoard and committee meetings and to provide required expertise on our boardBoard committees. As described above, the Nominating and Corporate Governance Committee recommends new members of our Board of Directors for their directorships.

In evaluating such directors,director candidates, our Nominating and Corporate Governance Committee has reviewed the experience, qualifications, attributes and skills of our directors and nominees, including those identified in the biographical information set forth above in the section entitled “Election of Directors.” The Nominating and Corporate Governance Committee believes that the members of ourthe Board of Directors offer insightful and creative views and solutions with respect to issues facing the Company. In addition, the Nominating and Corporate Governance Committee also believes that the members of ourthe Board of Directors function well together as a group. The Nominating and Corporate Governance Committee believes that the above-mentioned attributes and qualifications, along with the leadership skills and other experiences of the members of the Board of Directors described in further detail above under the section entitled “Election of Directors,” provide the Company with the perspectives and judgment necessary to guide the Company’s strategies and monitor their execution.

DisclosureWhen there is a vacancy on the Board, the Nominating and Corporate Governance Committee uses its network of contacts to compile a list of potential candidates, but may also engage, if it deems it appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Corporate Governance Committee meets to discuss and consider such candidates’ qualifications and then selects a nominee for recommendation to the Board by majority vote.

Diversity

The Board does not have a formal policy with respect to diversity. However, the Board believes that it is important that its members represent diverse viewpoints, with a broad array of experiences, professions, skills and backgrounds that, when considered as a group, provide a sufficient mix of perspectives to allow the Board to best fulfill its responsibilities to the long-term interests of the Company’s stockholders.

Board Renewal

The Board believes it is important to have experienced directors with a deep understanding of the Company’s business as well as other directors who bring fresh perspectives to the Board. In its efforts to identify potential director candidates, the Board and the Nominating and Corporate Governance Committee consider the input from the directors’ self-evaluation process to identify the backgrounds and expertise that are desired and the future needs of the Board in light of anticipated director retirements or resignations. The Board’s ongoing assessment of its collective skills, experience and expertise resulted in the recruitment of three new independent directors within the past three years.

In recruiting Alexandra Glucksmann, Ph.D., a new independent director in 2018, the Nominating and Corporate Governance Committee retained the search firm of Odgers Berndtson to help identify director prospects, perform candidate outreach, assist in reference and background checks and provide other related services. Our recruiting process typically involves either a search firm or a member of the Board or the Nominating and Corporate Governance Committee contacting a prospect to gauge the prospect’s interest and availability. A candidate will then meet with several members of the Board and then meet with members of the Company’s management as appropriate. At the same time, the Board or the Nominating and Corporate Governance Committee and the search firm will contact references for the prospect. A background check is completed before a final recommendation is made to the Board to appoint a candidate to the Board.

Meetings of the Board

The Board met five times during 2018. Each director attended 75% or more of the aggregate of the meetings of the Board and of the committees on which he or she served, held during the period for which he or she was a director or committee member.

Directors are encouraged, but not required, to attend our annual meetings of stockholders. Seven of our eight then-continuing directors attended our 2018 annual meeting of stockholders.

Compensation Committee CharterInterlocks and Insider Participation

WeNone of the members of the Compensation Committee is or has ever been an officer or employee of the Company. No executive officer of the Company serves as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving as a member of our Board or our Compensation Committee.

Performance Evaluations of the Board of Directors and its Committees

In accordance with our corporate governance guidelines and the Nominating and Corporate Governance Committee charter, the Board, with the assistance of the Nominating and Corporate Governance Committee, evaluates the performance of the Board, its committees and each individual director on an annual basis. Each member of the Board conducts an annual self-evaluation for the purpose of determining whether the Board and its committees are functioning effectively. As part of this process, each director considers the effectiveness of the Board and each committee on which the director serves. The results of the evaluations are discussed at subsequent meetings of the Board and its committees.

Director Nomination

The Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders and evaluate them using the same criteria as candidates identified by the Board or the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee may also take into consideration the number of shares of the Company’s common stock held by the recommending stockholder and the length of time that those shares have been held. To recommend a Disclosuredirector candidate for consideration by the Nominating and Corporate Governance Committee, a stockholder must submit the recommendation in writing to the Company, including the following information:

Recommendations and the information described above should be sent to our Corporate Secretary at REGENXBIO Inc., 9600 Blackwell Road, Suite 210, Rockville, Maryland 20850, Attention: Corporate Secretary.

Once a person has been identified by the Nominating and Corporate Governance Committee charter. Our Disclosureas a potential director candidate, the Nominating and Corporate Governance Committee may: collect and review publicly available information regarding the person to assess whether the person should be considered further; request additional information from the candidate and the proposing stockholder; contact references or other persons to assess the candidate; and conduct one or more interviews with the candidate. The Nominating and Corporate Governance Committee may consider that information in light of information regarding any other candidates that the Nominating and Corporate Governance Committee may be evaluating at that time, as well as any relevant director search criteria. The evaluation process generally does not vary based on whether or not a candidate is comprisedrecommended by a stockholder; however, as stated above, the Nominating and Corporate Governance Committee may take into consideration the number of our Chief Executive Officer; Chief Financial Officer; Chief Medical Officer; General Counsel;shares held by the recommending stockholder and certain other senior-level executive officers. Our General Counsel serves as the chairlength of the Disclosure Committee. The purpose of the Disclosure Committee istime that those shares have been held.

In addition to provide assistancerecommending director candidates to the Chief Executive OfficerNominating and Corporate Governance Committee, stockholders may also nominate candidates for election to the Chief Financial Officer in fulfilling their responsibilities regardingBoard at an annual meeting of stockholders. For more information, see “Questions and Answers About the identificationProxy Materials and disclosureVoting—May I propose actions for consideration at next year’s annual meeting of material information about us, and the accuracy, completeness and timeliness of our financial reports. Our Disclosure Committee meets at least once per quarter.stockholders or nominate individuals to serve as directors?”

Separation of CEO and Chairman of the Board and Chief Executive Officer Roles

OurThe Board of Directors separates the positions of Chairman of the Board and Chief Executive Officer.CEO. Separating these positions allows our Chief Executive OfficerCEO to focus on ourday-to-day business, while

allowing the Chairman of the Board to lead the Board of Directors in its fundamental role of providing advice to and independent oversight of management. The Board of Directors recognizes the time, effort, and energy that the Chief Executive OfficerCEO is required to devote to his position in the current business environment, as well as the commitment required to serve as our Chairman of the Board, particularly as the Board of Directors’Board’s oversight responsibilities continue to grow. We believe that having separate positions and having an outside director serve as Chairman of the Board is the appropriate leadership structure for the Company at this time.

Meetings of the Board of Directors

Our Board of Directors met 13 times during 2015. Each director attended 75% or more of the aggregate of the meetings of the Board of Directors and of the committees on which he or she served, held during the period for which he was a director or committee member.

Director Attendance at Annual Meetings of Stockholders

Directors are encouraged, but not required, to attend our annual stockholder meetings.

Stockholder Communications with the Board of Directors

Stockholders may communicate with the Board of Directors, including the independent members of the Board of Directors, by sending a letter to the Corporate Secretary, REGENXBIO Inc., 9712 Medical Center Drive, Suite 100, Rockville, MD 20850. Each such communication should set forth (1) the name and address of such stockholder, as they appear on the Company’s books and, if the shares of the Company’s stock are held by a nominee, the name and address of the beneficial owner of such shares, and (2) the number of shares of the Company’s stock that are owned of record by such record holder and beneficially by such beneficial owner. The Corporate Secretary will review all communications from stockholders, but may, in her sole discretion, disregard any communication that she believes is not related to the duties and responsibilities of the Board of Directors. If deemed an appropriate communication, the Corporate Secretary will submit a stockholder communication to a chairman of a committee of the Board of Directors, or a particular director, as appropriate.

Code of Business Conduct

We have adopted a code of business conduct that applies to each of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller and persons performing similar functions. The code addresses various topics, including: (1) compliance with applicable laws, rules and regulations; (2) conflicts of interest; (3) public disclosure of information; (4) insider trading; (5) corporate opportunities; (6) competition and fair dealing; (7) gifts; (8) discrimination, harassment and retaliation; (9) health and safety; (10) record-keeping; (11) confidentiality; (12) protection and proper use of company assets; (13) payments to government personnel; and (14) the reporting of illegal and unethical behavior.

The code of business conduct is posted in the corporate governance section of our website at www.regenxbio.com. Any waiver of the code of business conduct for an executive officer or director may be granted only by our Board of Directors or a committee thereof and must be timely disclosed as required by applicable law. We intend to disclose future amendments to certain provisions of our code of business conduct, or waivers of those provisions, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions on our website at www.regenxbio.com.

We have implemented whistleblower procedures that establish formal protocols for receiving and handling complaints from employees. Any concerns regarding accounting or audit matters reported under these procedures will be communicated promptly to the Audit Committee. The whistleblower policy is posted in the corporate governance section of our website at www.regenxbio.com.

Risk Oversight

OurThe Board of Directors has responsibility for the oversight of the company’sCompany’s risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes ourthe Board of Directors receiving regular reports from boardBoard committees and members of senior management to enable ourthe Board of Directors to understand the company’sCompany’s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic, reputational and reputationalcybersecurity risk. The oversight of risk within the Company is an evolving process requiring the Company to continually look for opportunities to further embed systematic enterprise risk management into ongoing business processes within the Company.

The Audit Committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the Audit Committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the Audit Committee includes direct communication with our external auditors,auditor, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The Compensation Committee is responsible for assessing whether any of our compensation policies or programs has the potential to encourage excessive risk-taking. The Nominating and Corporate Governance Committee manages risks associated with the independence of the Board, of Directors, corporate disclosuregovernance practices, and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by ourthe Board of Directors as a whole.

Communications with the Board

DIRECTOR COMPENSATION

During our fiscal year ended December 31, 2015, we paid cash feesThe Board is interested in receiving communications from stockholders and granted optionsother interested parties. These parties may contact any member of the Board or any committee of the Board, thenon-employee directors as a group or the chairperson of any committee. In addition, the Audit Committee is interested in receiving communications from employees and other interested parties regarding accounting, internal controls or auditing matters. Any such correspondence should be addressed to purchase shares of our common stockthe appropriate person or persons, either by name or title, and sent to our non-employee directors who served on our Board of Directors. A non-employee director is a director whoCorporate Secretary at REGENXBIO Inc., 9600 Blackwell Road, Suite 210, Rockville, Maryland 20850, Attention: Corporate Secretary. The Corporate Secretary will review all such communications, but may, in his or her sole discretion, disregard any communication that he or she believes is not employedrelated to the duties and responsibilities of the Board. If deemed an appropriate communication, the Corporate Secretary will share the communication with the applicable director or directors.

DIRECTOR COMPENSATION

Our Board determines the compensation of ournon-employee directors in conjunction with recommendations made by usthe Compensation Committee. We use a combination of cash and who does not receiveshare-based compensation from us (other than for services as a director) or have a business relationship with us that would require disclosure under certain SEC rules.to attract and retain qualified candidates to serve on the Board. Kenneth T. Mills, our presidentPresident and chief executive officerCEO and a member of ourthe Board, of Directors, did not receive any compensation from us during our fiscal year ended December 31, 20152018 for his service as a director and is not included in the table2018 Director Compensation Table below.

Fees Earned or Paid in Cash

As of December 31, 2015, the following non-employee directors held outstanding options to purchase shares of our common stock: Mr. Hayden (475,475 shares); Mr. Beshar (89,375 shares); Dr. Karabelas (49,375 shares); Dr. Engleman (25,000 shares); Mr. Fox (25,000 shares); Ms. Samuels (25,000 shares) and Dr. Stump (25,000 shares).

Non-Employee Director Compensation

Our Board of Directors, upon the recommendation of our Compensation Committee, adopted athen-effective compensation program fornon-employee directors, in August 2015. Pursuant to the program, each member of our Board of Directors who is not our employee will receive the following cash compensation for board services, as applicable:

Each of the above isapplicable, paid in quarterly installments in arrears.arrears:

In addition to the cash compensation described above, each member of the Board who served on the Audit Committee, Compensation Committee or Nominating and Corporate Governance Committee received additional cash compensation as follows, paid in quarterly installments in arrears:

In November 2018, the Board, upon the recommendation of the Compensation Committee, amended our compensation program fornon-employee directors, effective as of January 1, 2019. Based on peer group data and analysis provided by Radford, the annual cash compensation level was increased for each service listed in the table above except Chairman of the Board. We have filed a copy of the program, as amended, as Exhibit 10.12 to the Annual Report.

Option Awards

Non-employee members of ourthe Board of Directors receive automatic grants ofnon-statutory stock options under our 2015 Equity Incentive Plan. Eachnon-employee director upon joining ourthe Board of Directors willis automatically be granted anon-statutory stock option to purchase 25,000 shares of our common stock with an exercise price equal to the fair market value of our common stock on the grant date. Each of these options will vestvests in equal monthly installments over the 36 months following the date of the grant, and each provides for full acceleration in the event of a change ofin control.

In addition, on the date of each annual meeting of our stockholders, eachnon-employee director willis automatically be granted anon-statutory stock option to purchase 12,500 shares of our common stock with an exercise price equal to the fair market value of our common stock on the grant date. Anon-employee director who receives an initial award will not receive the additional annual award in the same calendarfor that year. The annual grants vest in equal monthly installments over the 12 months following the date of the grant, and each provides for full acceleration in the event of a change ofin control.

Other Compensation

We will also continue to reimburse ournon-employee directors for their reasonableout-of-pocket expenses incurred in attending boardBoard and committee meetings. We also provide customary director and officer insurance for all directors.

Pursuant2018 Director Compensation Table

The following table sets forth a summary of the compensation we paid to ournon-employee directors in 2018:

As of December 31, 2018, ournon-employee directors held the letter agreement he entered into with us on February 6, 2013, Mr. Hayden, the Chairman of our Board of Directors, agreed to serve as a member of our Board of Directors. In consideration of such services, we agreed to pay Mr. Hayden an annual fee of $40,000. Pursuant to his letter agreement, we issued Mr. Hayden an optionfollowing outstanding options to purchase 6,420,000 Class B Preferred Units of our predecessor limited liability company. In connection with our conversion to a C-corporation in September 2014, Mr. Hayden’s Class B Preferred Units were cancelled and Mr. Hayden received an option to purchase 354,100 shares of our common stock. We terminated the letter agreement with Mr. Hayden upon completion of our initial public offering in September 2015 (the IPO), and Mr. Hayden is compensated in accordance with the provisions of our compensation program for non-employee directors.

PROPOSAL 22:

RATIFICATION OF SELECTIONAPPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016

The Audit Committee of ourthe Board of Directors has selected PricewaterhouseCoopers LLP, anPwC as our independent registered public accounting firm asto perform the audit of our independent auditorsfinancial statements for the year ending December 31, 2016,2019, and has further directed that management submit thethis selection of independent auditors for ratification by our stockholders at the Annual Meeting. PricewaterhouseCoopers LLPPwC has auditedserved as our financial statements for the years ended December 31, 2015, 2014 and 2013.independent registered public accounting firm since 2015. Representatives of PricewaterhouseCoopers LLPPwC are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

The Audit Committee believes that the continued retention of PwC is in the best interests of the Company and our stockholders. As provided in the Audit Committee charter, the Audit Committee is directly responsible for the appointment, retention, compensation and oversight of the independent registered public accounting firm retained to audit the Company’s financial statements. The Audit Committee annually reviews the independent registered public accounting firm’s independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the performance, objectivity or independence of the independent registered public accounting firm.

In determining whether to reappoint PwC as the Company’s independent registered public accounting firm, the Audit Committee took into consideration a number of factors, including the length of time the firm has been engaged, the quality of the Audit Committee’s ongoing discussions with PwC, an assessment of the professional qualifications and past performance of PwC and the potential impact of changing independent registered public accounting firms. Through its experience with the Company, PwC has gained institutional knowledge and expertise regarding the Company’s operations, accounting policies and practices and internal control over financial reporting. The Audit Committee believes that appointing a new independent registered accounting firm would require a significant time commitment that could interfere with management’s focus on financial reporting and internal controls.

Neither our amended and restated bylawsBylaws nor other governing documents or laws require stockholder ratification of the selection of PricewaterhouseCoopers LLPPwC as our independent registered public accounting firm. However, the Audit Committee of the Board of Directors is submitting the selection of PricewaterhouseCoopers LLPPwC to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee of the Board of Directors will reconsider whether or not to retain PricewaterhouseCoopers LLP.PwC. Even if the selection is ratified, the Audit Committee of our Board of Directors in its discretion may direct the appointment of a different independent auditorsregistered public accounting firm at any time during the year if it determines that such a change would be in the best interests of the Company and our stockholders.

Vote Required

In order for Proposal 2 to pass, holdersthe number of a majorityvotes cast “For” Proposal 2 must exceed the number of all those outstanding shares present in person, or represented by proxy, andvotes cast either affirmatively or negatively at the Annual Meeting must vote “FOR”against Proposal 2. Abstentions and brokernon-votes will be counted towards a quorum; however, they will not be counted either “FOR”“For” or “AGAINST”“Against” the proposal and will have no effect on the proposal. BecauseWe do not expect to receive brokernon-votes on this proposal because the ratification of the appointment of the independent registered public accounting firm is a matter on which a bank, brokerbanks, brokers or other nominee isnominees are generally empowered to vote no broker non-votes are expected to exist in connection with this matter.any shares for which a beneficial owner does not provide voting instructions.

Independent Registered Public Accounting Firm’s Fees

The following table represents aggregate fees billed to REGENXBIOthe Company for the years ended December 31, 20152018 and December 31, 2014,2017, by PricewaterhouseCoopers LLP,PwC, our principal accountant.independent registered public accounting firm:

Audit Fees

Audit fees consist of aggregate fees billed or incurred by PwC for professional services rendered in connection with the annual audit of our financial statements, including internal control attestation for the year ended December 31, 2018, quarterly review procedures, consents issued for our registration statements and securities offerings.

Audit-Related Fees

Audit-related fees consist of fees billed or incurred by PwC for due diligence services related to mergers and acquisitions rendered during the year ended December 31, 2017.

All Other Fees

All other fees consist of license fees billed or incurred by PwC for access to its proprietary disclosure checklist software platform.

All audit fees, audit-related fees and other fees described above werepre-approved by the Audit Committee in accordance with applicable SEC requirements.

Pre-Approval Policies and Procedures

The Audit Committee’s policy is topre-approve all audit and permissiblenon-audit services rendered by PricewaterhouseCoopers LLP,PwC, our independent registered public accounting firm. The Audit Committee canpre-approve specified services in defined categories of audit services, audit-related services, tax services and taxall other services up to specified amounts, as part of the Audit Committee’s approval of the scope of the engagement of PricewaterhouseCoopers LLPPwC or on an individualcase-by-case basis before PricewaterhouseCoopers LLPPwC is engaged to provide a service. The Audit Committee has determined that

Recommendation of the rendering of tax-related services by PricewaterhouseCoopers LLP is compatible with maintaining the principal accountant’s independence for audit purposes. PricewaterhouseCoopers LLP has not been engaged to perform any non-audit services.Board

YOURTHE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS YOU “FOR”A VOTE FOR“FOR” THE RATIFICATION OF PRICEWATERHOUSECOOPERS LLPTHE APPOINTMENT OF PWC AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 20162019.

REPORT OF THE AUDIT COMMITTEE¹ REPORT

The Audit Committee of the Board of Directors consisted on December 31, 20152018 of the threenon-employee directors named below. The Board of Directors annually reviews the NASDAQNasdaq listing standards’ definition of independence for Audit Committee members (including the requirements ofRule 10A-3 promulgated under the Securities Exchange Act of 1934, as amended)Act) and has determined that each member of the Audit Committee meets that standard. Mr.Each of Daniel J. Abdun-Nabi and Luke M. Beshar serves as an audit committee financial expert in accordance with applicable SEC regulations.

The principal purpose of the Audit Committee is to assist the Board of Directors in its general oversight of ourthe Company’s accounting and financial reporting processes and audits of ourthe Company’s financial statements. The Audit Committee is responsible for selecting and engaging ourthe Company’s independent auditor and approving the audit andnon-audit services to be provided by the independent auditor. The Audit Committee’s function is more fully described in its charter, which the Board of Directors has adopted and which the Audit Committee reviews and approves on an annual basis.

OurThe Company’s management is responsible for preparing ourthe Company’s financial statements and ourfor the Company’s financial reporting process. PricewaterhouseCoopers LLP, ourPwC, the Company’s independent registered public accounting firm, is responsible for performing an independent integrated audit of ourthe Company’s financial statements and expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the United States and attesting to the effectiveness of our internal control over financial reporting.States.

The Audit Committee has also reviewed and discussed with PricewaterhouseCoopers LLPthe Company’s management the audited financial statements in ourthe Annual Report on Form 10-K for the year ended December 31, 2015 (the 10-K).Report. In addition, the Audit Committee discussed with PricewaterhouseCoopers LLPPwC those matters required to be discussed by Statement of Accounting Standards 114, as modified, as adopted by theunder applicable Public Company Accounting Oversight Board (“PCAOB”) rules or “PCAOB,” in Rule 3200T and by PCAOB Auditing Standard No. 16, Communications with Audit Committees, as may be further modified or supplemented.standards. Additionally, PricewaterhouseCoopers LLPPwC provided to the Audit Committee the written disclosures and the letter required byunder applicable PCAOB Rule 3526 “Communication with Audit Committees concerning independence” as adopted by the Public Company Accounting Oversight Board.rules or standards. The Audit Committee also discussed with PricewaterhouseCoopers LLPPwC its independence from the Company.

Based upon the review and discussions described above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the 10-KAnnual Report for filing with the United States Securities and Exchange Commission. We haveSEC. The Audit Committee has selected PricewaterhouseCoopers LLPPwC as the Company’s independent registered public accounting firm for the year ended December 31, 2016,2019, and havehas approved submitting the selection of the independent registered public accounting firm for ratification by the Company’s stockholders.

Submitted

The material in this Audit Committee Report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such material by reference.

PROPOSAL 3:

ADVISORY VOTE ON EXECUTIVE COMPENSATION

In accordance with Section 14A of the Exchange Act, we are holding a stockholder advisory vote on the compensation of our named executive officers, or a“say-on-pay vote,” as described in the “Executive Compensation” section, the tabular disclosure regarding such compensation and the accompanying narrative disclosure set forth in this Proxy Statement. At the Annual Meeting, stockholders will be asked to approve the following resolution:

RESOLVED, that the stockholders of REGENXBIO Inc. (the “Company”) hereby approve, on anon-binding advisory basis, the compensation of the Company’s named executive officers, including the Compensation Discussion and Analysis and compensation tables thereto, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.

The Compensation Committee oversees and administers our executive compensation program, including the evaluation and approval of compensation plans, policies and programs offered to our named executive officers. Our executive compensation program is designed to meet the following objectives:

Please see the “Executive Compensation” section of this Proxy Statement for a detailed discussion about our executive compensation program, including information about the 2018 compensation of our named executive officers.

While this vote is being conducted on an advisory basis, and is therefore not binding on us, the vote will be carefully considered by the Compensation Committee and the Board. Both the Compensation Committee and the Board value the opinions of our stockholders and, to the extent there is any meaningful vote against the compensation of our named executive officers as disclosed in this Proxy Statement, we will consider our stockholders’ concerns and evaluate what actions, if any, may be appropriate to address those concerns. The outcome of the vote, however, will not be construed as overruling any prior decision by the Company, the Compensation Committee or the Board.

Vote Required

In order for Proposal 3 to pass, the number of votes cast “For” Proposal 3 must exceed the number of votes cast “Against” Proposal 3. Abstentions and brokernon-votes will not be counted either “For” or “Against” the proposal and will have no effect on the proposal.

Recommendation of the Board

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL, ON AN ADVISORY BASIS, OF THE 2018 COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

PROPOSAL 4:

ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON

EXECUTIVE COMPENSATION

In addition to the stockholder advisory vote on executive compensation, we are also holding a stockholder advisory vote as to the frequency with which stockholders would have an opportunity to provide an advisory determination on executive compensation. Under SEC rules, this vote on frequency is required once every six years.

For the reasons described below, we recommend that our stockholders approve the following resolution, which is to implement a frequency of every three years, or a triennial vote, on executive compensation.

RESOLVED, that the stockholders of REGENXBIO Inc. (the “Company”) hereby approve, on anon-binding advisory basis, a triennial vote by the stockholders of the Company, on anon-binding advisory basis, on the compensation of the Company’s named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission.

Our Board believes that a triennial vote on executive compensation is the best approach for the Company based on a number of considerations, including the following:

While this vote is being conducted on an advisory basis, and is therefore not binding on us, the vote will be carefully considered by the Compensation Committee and the Board. Both the Compensation Committee and the Board value the opinions of our stockholders and, we will consider the outcome of the vote when determining the frequency of future advisory votes to approve executive compensation. The outcome of the vote, however, will not be construed as overruling any prior decision by the Company, the Compensation Committee or the Board.

Vote Required

In voting on Proposal 4, you can choose whether the advisory vote on executive compensation should be conducted every one year, every two years or every three years. You may also abstain from voting on this item. The approval requirement for this proposal is a plurality of the votes cast. The frequency option receiving the most votes cast by stockholders will be the frequency that is recommended by stockholders. Abstentions and brokernon-votes will have no effect on the outcome of the proposal.

Recommendation of the Board

THE BOARD UNANIMOUSLY RECOMMENDS THAT FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION BE HELD EVERY 3 YEARS.

EXECUTIVE OFFICERS

The names of the current executive officers of the Company and certain information about each of them are set forth below:

Kenneth T. Mills. For information regarding Mr. Mills, our President and CEO and a member of our Board, see “Proposal 1: Election of Directors.”

Vittal “Vit” Vasista, age 51, has been our Chief Financial Officer since August 2009. Prior to joining us, Mr. Vasista served as Principal at PRTM Management Consultants from October 2006 to July 2009, where he developed operational strategies for both private and public organizations, including the development of market entry strategies, innovative business models, and operational improvements. Mr. Vasista received an M.B.A. from The Wharton School at the University of Pennsylvania, an M.S. in Mechanical Engineering from Stanford University, and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

Olivier Danos, Ph.D., age 61, has been our Chief Scientific Officer since March 2017. Prior to joining us, Dr. Danos was the Senior Vice President, Cell and Gene Therapy at Biogen Inc., a biotechnology company, from September 2014 until March 2017, where he led its gene therapy research and development activities. From September 2011 to September 2014, Dr. Danos was the Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals. Prior to Kadmon, Dr. Danos served as the Director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital—Enfants Malades in Paris. He also served as the Chief Scientific Officer at Genethon and Senior Director of Research at Somatix Therapy Corporation, and held senior roles at the French National Centre for Scientific Research and the Pasteur Institute in Paris. Dr. Danos is the former President and founding member of the European Society of Gene and Cell Therapy. Dr. Danos received a Ph.D. in Biology from the Pasteur Institute and University of Paris Diderot and a Master in Science in Genetics and Molecular Biology at the University of Paris Orsay.

Curran Simpson, age 57, is currently our Senior Vice President, Product Development and Chief Technology Officer, and served as our Senior Vice President, Technical Operations from August 2015 to August 2018. Prior to joining us, Mr. Simpson was the Regional Supply Chain Head for North America at GlaxoSmithKline plc (“GSK”), a pharmaceutical company, from December 2012 until August 2015. Mr. Simpson was the Senior Vice President, Operations at the Human Genome Sciences division of GSK (“HGS”) from July 2006 to December 2012, as well as the Vice President, Manufacturing Operations at HGS from January 2003 to June 2006. Prior to HGS, Mr. Simpson held various positions with Biogen, Inc., Covance Biotechnology Services Inc., Novo-Nordisk Biochem Inc., Genentech, Inc. and Genencor, Inc. Mr. Simpson received an M.S. in Surface and Colloid Science (Physical Chemistry) from Clarkson University and a B.S. in Chemistry/Chemical Engineering from Clarkson College of Technology.

Patrick J. Christmas, age 48, has been our Senior Vice President, General Counsel since August 2016. Prior to joining us, Mr. Christmas served as Interim General Counsel at Tolero Pharmaceuticals, Inc. from April 2015 until August 2016. From May 2011 until November 2014, Mr. Christmas was the Vice President, General Counsel of Lumara Health, a specialty pharmaceutical company. Prior to Lumara Health, Mr. Christmas was General Counsel at the Wellstat Companies, a group of biotechnology companies, from July 2007 until May 2011 and General Counsel at BioVeris Corporation, a publicly held diagnostics company, from April 2005 to July 2007. Mr. Christmas began his career as an Associate at the law firm of Akin Gump Strauss Hauer & Feld LLP. Mr. Christmas received a J.D. from the University of Notre Dame and a B.A. in Economics from Boston College.

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

This Compensation Discussion and Analysis (“CD&A”) explains our compensation philosophy, policies and decisions for 2018 for the following executives, whom we refer to in this CD&A and in the related tables as our named executive officers (“NEOs”):

Transition from Emerging Growth Company Status

Prior to December 31, 2018, we were considered an “emerging growth company” under applicable federal securities laws and, as a result, we have not previously been required to provide a CD&A regarding our executive compensation program or hold advisory votes on the compensation of our NEOs or with respect to the frequency of such votes. As a result, the Annual Meeting marks the first time stockholders will vote, on an advisory basis, on the compensation of our NEOs and the frequency with which such votes should be conducted. As such, this CD&A and the related executive compensation tables are intended to provide a detailed summary of our executive compensation program.

Executive Summary of Our 2018 Achievements

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our NAV Technology Platform, a proprietary adeno-associated virus (“AAV”) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. We and our third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

In 2018, we made significant progress toward our clinical development and business objectives, including the following achievements, which impacted executive compensation:

Compensation Philosophy and Objectives

The rapidly growing gene therapy industry has created a competitive recruitment and retention market for strong talent. It is our goal to ensure that we have the most skilled, innovative and resourceful executives on our leadership team. We foster an environment at REGENXBIO that will attract and retain top talent, and our executive compensation program is designed to support those objectives. Our program is structured around the following philosophy and objectives:

2018 all other neo compensation at-risk performance-based vs. guranteed all other neo compensation for 2018 2018 ceo compensation at-risk performance-based vs. guranteed ceo compensation for 2018

Oversight and Operation of our Executive Compensation Program

Our executive compensation program demonstrates a commitment to a robust process and strong corporate governance practices, as evidenced by the following:

What We Do:

What We Don’t Do:

Our Compensation Committee conducts a compensation risk assessment annually. The Compensation Committee believes that the mix of long-term equity incentives, short-term cash incentives and base salary appropriately balances both short-term and long-term performance goals.

Process of Determining Executive Compensation

Role of the Compensation Committee and the Board. Our Compensation Committee has been delegated the authority to make determinations regarding all elements of compensation for our executives. The Compensation Committee engages an independent compensation consultant to advise them on the competitiveness of the executive compensation program, including an annual peer group review and annual analysis of all elements of executive compensation for each executive. Compensation packages for each executive are typically finalized and approved at the first Compensation Committee meeting each year. The independent members of the Audit Committee:Board ratify recommendations made by the Compensation Committee with respect to the compensation and performance objectives of our President and CEO.

Luke M. Beshar, ChairmanRole of Management. Our Compensation Committee, in making executive compensation decisions, may solicit input from management as appropriate with respect to individual and Company performance and results. The Compensation Committee receives recommendations and evaluations with respect to the compensation and performance of our executives from our President and CEO (except for his own compensation and performance). The Senior Vice President, Human Resources works with the compensation consultant to provide any internal data it requires. The Compensation Committee considered assessments from management when making 2018 compensation decisions.

David C. Stump, M.D.Role of the Compensation Consultant. Our Compensation Committee is authorized to select and retain its own independent compensation consultant. The Compensation Committee retained Radford in this role from May 2015 to March 2019. During that time, Radford annually conducted a comprehensive assessment of our executive compensation program and pay levels. Radford advised the Compensation Committee on evolving best practices in executive compensation and provided benchmarking data and recommendations. Since April 2019, the Compensation Committee has retained Willis Towers Watson in this role. The Compensation Committee conducted an evaluation of each of Radford and Willis Towers Watson and concluded that neither engagement raised any conflict of interest.

Camille SamuelsPeer Group Data. Our Compensation Committee, upon advice received from its independent compensation consultant, selected the 20 companies that comprised our peer group for determining 2018 compensation through a screening process that considered publicly traded biopharmaceutical companies similar to us in headcount and market capitalization.

Our 2018 peer group companies were as follows:

Survey Data. In addition to using peer group data, the Compensation Committee used survey data from the Radford Global Life Sciences Survey as of July 1, 2017 to inform compensation decisions for 2018. The custom data cut included 107 publicpre-commercial biotechnology companies with a median headcount of 67 and a median market capitalization of approximately $667 million.

Elements of Compensation

The compensation paid to our NEOs in 2018 included the following elements:

The elements of our 2018 executive compensation program and compensation decisions for NEOs are described in further detail below.

Base Salary

Our Compensation Committee reviews and sets base salaries for NEOs, other than the President and CEO, on an annual basis in January of each year. Our Board determines the base salary for our President and CEO based on the recommendation of the Compensation Committee.

Our Compensation Committee and Board seek to establish and maintain base salaries for each position and level of responsibility that are competitive with those of executives at our peer group companies. In determining the base salary for each executive, the Compensation Committee takes many factors into account, including but not limited to:

Our NEOs were given merit increases to their base salaries in 2018 as a result of their respective performances in 2017. These merit increases were generally aligned with those provided to all other employees. The base salaries for our NEOs were adjusted as follows in 2018:

Annual Short-Term Cash Incentive

We have an annual cash incentive program for all employees, which is intended to align corporate, departmental, and individual goals throughout the Company and to provide an incentive that further ties compensation to achievement of those goals. In establishing targets for the cash incentive awards for our NEOs, the Compensation Committee (and the Board, in the case of our President and CEO) considers cash incentive awards paid to executives in similar positions at our peer group companies.

For 2018, target cash incentive award percentages were adjusted from the prior year as follows:

For 2018, our Compensation Committee determined that the cash incentive awards for our NEOs except for our President and CEO, Mr. Mills, would be determined based on corporate and individual objectives. Given Mr. Mills’ more substantial influence on the overall performance of the Company, the Compensation Committee believed it was appropriate and in the best interests of our stockholders to have Mr. Mills’ cash incentive award be based solely upon the achievement of corporate objectives, and the independent Board members concurred. The Compensation Committee believes that including the achievement of individual goals as a component of our cash incentive award payouts is important to motivate our NEOs other than Mr. Mills, as we continue to progress toward the commercial phase of our Company. For 2018, weightings allocated to corporate and individual objectives were as follows:

The Company’s annual cash incentive program, which is approved by the Compensation Committee and applicable to all employees, utilizes both a corporate performance multiplier and an individual performance multiplier. The corporate performance multiplier is based on the degree to which the Company’s objectives have been achieved during the relevant year; this multiplier is determined by the Compensation Committee and may range from 0 to 200% of target, provided that, if it is determined to be less than 50% of target, there will be no

payout for the portion of our annual incentive program that is attributable to corporate performance. The individual performance modifier is based on the degree to which each employee’s individual objectives have been achieved during the relevant year; this multiplier is approved by the Compensation Committee for each of our NEOs and may range from 0 to 200% of target.

Corporate Objectives

Near the beginning of each year, our management recommends annual corporate objectives to our Compensation Committee and Board for approval. These objectives serve as the basis for determining our performance against key strategic and operating parameters for the year.

The Compensation Committee (and the Board, with respect to our President and CEO) approved the corporate objectives and weightings for 2018 as reflected in the table below. At the time of approval, the Compensation Committee believed that these objectives were challenging but attainable, and that attainment was uncertain.

Individual Objectives

Our President and CEO, in consultation with our other NEOs, established individual objectives for each of our other NEOs near the beginning of 2018 that were specific to each of their respective areas of responsibility and supported meeting our corporate objectives. These individual objectives were then recommended to and approved by our Compensation Committee. At the time of approval, the Compensation Committee believed these objectives were challenging but attainable, and that attainment was uncertain.

Our Compensation Committee, with input from our President and CEO, made a qualitative determination following the end of the year as to the level of achievement of the respective individual objectives by each of our NEOs, other than our President and CEO.

Determining Payouts of Annual Cash Incentives

With respect to our 2018 corporate objectives, our Board and Compensation Committee determined that we achieved a payout percentage of 160% of target based on our corporate performance. When assessing the payouts, the Board and Compensation Committee took into account our overall financial condition at the time and our performance relative to our annual corporate objectives. The Compensation Committee determined that all NEOs were instrumental in exceeding our corporate objectives.

The Compensation Committee viewed the advancement of our clinical programs, entry into the license agreement with Abeona and completion of the year with more than $470 million in cash, cash equivalents and marketable securities as key achievements in an exceptional year for the Company. Our negotiation and execution of certain license agreement amendments with AveXis, along with the subsequent acquisition of AveXis by Novartis, was viewed as an additional achievement outside of thepre-established corporate

objectives. This acquisition further validated our NAV Technology Platform, and our negotiation and execution of the license agreement amendments helped maintain the financial strength of the Company through the receipt of $180 million in 2018. See “—Executive Summary of Our 2018 Achievements” above for further information regarding these achievements.

The determination of the Compensation Committee and Board regarding our performance relative to each corporate objective is shown in the following table:

Based on the Company’s level of performance in 2018 relative to our corporate goals, and based on the level of performance of each NEO other than our President and CEO in 2018 relative to individual goals, our NEOs earned the cash incentive awards shown in the following table for 2018:

Long-term Equity Incentives

Equity awards are crucial to a competitive compensation program for executives because they act as a powerful retention incentive. Equity ownership in our Company by our NEOs also aligns the interests of our NEOs with those of our stockholders and rewards our NEOs for their contributions to the long-term success of the Company.

In determining the equity incentive awards for our NEOs in 2018, our Board, with respect to our President and CEO, and our Compensation Committee, with respect to our other NEOs, considered the roles and performance of each NEO as well as the benchmarking data and recommendations of the Compensation Committee’s independent compensation consultant, which included information regarding equity compensation received by executives at peer group companies, as well as broader survey data. Based on these considerations, our NEOs received the stock option awards shown in the following table in 2018:

All options in the above table have an exercise price of $35.80, which was the closing price of our common stock on the relevant grant date. Shares of our common stock underlying the options in the above table will vest over a four-year period, with 25% of the shares vesting after 12 months from the date of grant and the balance vesting in equal monthly installments over the 36 months thereafter, provided that the optionee provides continuous service to the Company.

The Board, with respect to our President and CEO, and the Compensation Committee, with respect to our other NEOs, has also granted stock options and restricted stock units from time to time, outside of our annual equity incentive awards, in recognition of an NEOs expanded roles or continuing contributions to the Company’s performance. No such grants were made in 2018.

We typically grant stock options to new hires, including our executives, upon their commencing employment with us. Stock options allow employees to purchase shares of our common stock at a price per share equal to the fair market value of our common stock on the date of grant and may or may not be intended to qualify as “incentive stock options” for U.S. federal income tax purposes. Awards to newly hired employees generally vest over a four-year period, with 25% of the shares vesting after 12 months from the date of grant and the balance vesting in equal monthly installments over the 36 months thereafter, provided that the optionee provides continuous service to the Company.

Health, Welfare and Retirement Benefits

Our NEOs are eligible to participate in our health and welfare plans to the same extent as all full-time employees are eligible, including reimbursement of certain medical expenses of the NEO or employee and, if applicable, his or her eligible dependents. We pay a portion of the premium cost for our group health plan for all participants, including our NEOs. Other health and welfare benefits include medical, dental, vision and life insurance, flexible spending accounts and short- and long-term disability.

We have established a 401(k)tax-deferred savings plan, which permits all participants, including our NEOs, to make contributions by salary deduction pursuant to Section 401(k) of the Code. We are responsible for administrative costs of the 401(k) plan. We may, at our discretion, make matching contributions to the 401(k) plan. We do not generally provide our NEOs with any other perquisites or personal benefits.

Our employee stock purchase plan permits participants, including our NEOs, to purchase our common stock at a discount on atax-qualified basis through payroll deductions. The employee stock purchase plan is designed to qualify as an “employee stock purchase plan” under Section 423 of the Code. The purpose of the employee stock purchase plan is to encourage our employees, including our NEOs, to become our stockholders and better align their interests with those of our other stockholders.

Severance and Change in Control Benefits

We have entered into employment agreements with each of our NEOs which, among other things, provide for certain severance and change in control payments under certain circumstances. We believe these potential benefits discourage turnover and allow our NEOs to respond to the possibility of a change in control without being influenced by the potential effects of a change in control on their job security. These potential benefits and our employment agreements with our NEOs are described in further detail under “—Employment Agreements and Potential Payments Upon Termination or Change in Control.”

Tax and Accounting Considerations

Our Compensation Committee considers tax and accounting implications in determining all elements of our compensation plans, programs and arrangements. For taxable years prior to 2018, Section 162(m) of the Code generally denied a deduction to any publicly-held corporation for compensation paid to its named executive officers (other than the chief financial officer) exceeding $1.0 million, unless such compensation qualified as performance-based compensation. Base salaries, time-vested restricted stock, time-vested retention and transition payments, and discretionary or subjectively determined bonus awards generally did not qualify as performance-based compensation. However, pursuant to the Tax Cuts and Jobs Act of 2017 (the “TCJA”), for taxable years beginning in 2018, Section 162(m) of the Code no longer exempted qualified performance-based compensation from its restriction on deductions, other than with respect to compensation paid pursuant to a written binding contract that was in effect on November 2, 2017 and that was not materially modified after such date. In addition, the TCJA provides that the chief financial officer is no longer excluded from the named executive officers for purposes of its restriction on deductions. Further, once an individual’s compensation is subject to the restriction, his or her compensation will remain subject to the restriction regardless of whether he or she remains an NEO.

Anti-Hedging and Pledging Policy

As part of our policy against insider trading, our directors, officers, employees and certain other individuals are prohibited from purchasing financial instruments that are designed to hedge or offset any decrease in the market value of the Company’s securities. Additionally, such individuals are prohibited from engaging in transactions involving options on the Company’s securities, such as puts, calls and other derivative securities, except when receiving or exercising options granted by the Company. “Short sales” of the Company’s securities (sales of securities not already owned) are also prohibited. Furthermore, pledging of any Company securities is not permitted without the prior approval of the Company.

Compensation Committee Report

The Compensation Committee has reviewed and discussed the foregoing Compensation Discussion and Analysis with management. Based on this review and discussion, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and incorporated by reference into the Company’s Annual Report on Form10-K for the fiscal year ended December 31, 2018.

The material in this Compensation Committee Report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such material by reference.

2018 Summary Compensation Table

The following table provides information concerning the compensation earned by our NEOs during the years ended December 31, 2018, 2017 and 2016:

2018 Grants of Plan-Based Awards

The following table sets forth certain information regarding grants of plan-based awards to our NEOs during the year ended December 31, 2018. No other plan-based awards were granted to any of our current or former NEOs during 2018.

Outstanding Equity Awards at 2018 FiscalYear-End

The following table sets forth information regarding each outstanding and unexercised option held by each of our NEOs as of December 31, 2018. The number of shares subject to each award and, where applicable, the exercise price per share, reflects all changes as a result of our capitalization adjustments. The vesting schedule applicable to each outstanding award is described in the footnotes to the table below.